Fluidigm Corporation (FLDM)
-NasdaqGS 17.14 
0.61(3.44%) 4:00PM EDT|After Hours
:
17.14 0.00 (0.00%) 4:31PM EDT
| Prev Close: | 17.75 |
|---|
| Open: | 17.71 |
|---|
| Bid: | 9.57 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 19.60 |
|---|
| Beta: | 1.2 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 17.08 - 17.78 |
|---|
| 52wk Range: | 12.53 - 19.96 |
|---|
| Volume: | 74,187 |
|---|
| Avg Vol (3m): | 115,005 |
|---|
| Market Cap: | 435.70M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.68 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Opportunities in Hepatitis C and Genomic Technologies: a Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.Wall Street Transcript(Tue, May 21)
- FLUIDIGM CORP FinancialsEDGAR Online Financials(Fri, May 17)
- Fluidigm Passes This Key Testat Motley Fool(Thu, May 16)
- Saskatchewan Disease Control Laboratory Selects Fluidigm BioMarkTM HD Platform to Track Infectious AgentsBusiness Wire(Thu, May 9)
- FLUIDIGM CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Fluidigm to Present at the Bank of America Merrill Lynch 2013 Health Care ConferenceBusiness Wire(Tue, May 7)
- Why Fluidigm Shares Jumpedat Motley Fool(Thu, May 2)
- Fluidigm Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Fluidigm Reports Strong Q1 2013 ResultsBusiness Wire(Wed, May 1)
- FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- Fluidigm to Develop and Supply a Custom High-throughput Prep System for HLA TypingBusiness Wire(Wed, May 1)
- Q1 2013 Fluidigm Corp Earnings Release - After Market CloseCCBN(Wed, May 1)
- Rapid Development in HCV Space Leading FDA to be More Cautious: An Expert Analyst Discusses the Regulatory Environment for Pharmaceuticals with The Wall Street TranscriptWall Street Transcript(Fri, Apr 26)
- Fluidigm to Announce Q1 2013 Financial Results and Host Conference Call for InvestorsBusiness Wire(Wed, Apr 24)
- FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Mon, Apr 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 8.07 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.62 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.18 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -1.17 |
|---|
Business Summary
Fluidigm Corporation develops, manufactures, and markets microfluidic systems for academic research institutions, clinical laboratories, pharmaceutical companies, and biotechnology and Ag-Bio companies.
View More